Skip to main content
SpringerLink
Log in

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection

  • Papers Given at the 12th European Workshop on Inflammation, Halle, Germany, May 30–31, 1990
  • New Substances
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

Leflunomide has been shown to be very effective in preventing and curing several autoimmune animal diseases. Further, this agent is as effective as cyclosporin A in preventing the rejection of skin and kidney transplants in rats. Preliminary results from patients suffering from severe cases of rheumatoid arthritis demonstrated that clinical and immunological parameters could be improved with leflunomide therapy. Mode of action studies revealed that this substance antagonizes the proliferation inducing activity of several cytokines and is cytostatic for certain cell types. In this light, we could show that tyrosine phosphorylation of the RR-SRC peptide substrate and the autophosphorylation of the epidermal growth factor (EGF) receptor were, dose dependently, inhibited by leflunomide. EGF activates the intrinsic tyrosine kinase of its receptor, which stimulates the phosphorylation of a variety of peptides, the amino acid residue in all cases is tyrosine. These results indicate that much of leflunomide's activity could be due to the inhibition of tyrosine-kinase(s), which is an important general mechanism for the proliferation of various cell types. Thus, leflunomide, which is effective against autoimmune diseases and reactions leading to graft rejection, would seem to have a mode of action separating it from known immunosuppressive drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. R. R. Bartlett, T. Mattar, U. Weithmann, H. Anagnostopulos, S. Popovic and R. Schleyerbach,Leflunomide (HWA 486): a novel immunorestoring drug. InTherapeutic approaches to inflammatory diseases (Eds. A. J. Lewis, N. S. Doherty and N. R. Ackerman), Elsevier Science Publishing Co., Inc. New York, pp. 215–228 (1989).

    Google Scholar 

  2. R. R. Bartlett and R. Schleyerbach,Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity I. Disease modifying action on adjuvant arthritis of the rat. Int J. Immunopharmac.7, 7–18 (1985).

    Article  Google Scholar 

  3. R. R. Bartlett, R. X. Raiss, S. Popovic and R. Schleyerbach,Immunologic, histologic and ultrastructural studies in autoimmune MRL/1 mice. InArticular cartilage biochemistry (Eds. K. E. Kuettner, R. Schleyerbach and V. C. Hascall), pp. 391–412 (1986).

  4. S. Popovic and R. R. Bartlett,Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents and Actions19, 313–314 (1986).

    Article  PubMed  Google Scholar 

  5. S. Popovic and R. R. Bartlett,The use of the murine chronic graft versus host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents and Actions21, 284–286 (1987).

    Article  PubMed  Google Scholar 

  6. R. D. Pasternak, N. S. Wadopian, R. N. Wright, P. Siminoff, J. A. Gylys and J. P. Buyniski,Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. Agents and Actions21, 241–243 (1987).

    Article  PubMed  Google Scholar 

  7. R. R. Bartlett, S. Popovic and R. X. Raiss,Development of autoimmunity in MRL/lpr mice and the effect of drugs on this murine disease. Scand. J. Rheumatol. Suppl.75, 290–299 (1988).

    Google Scholar 

  8. P. Hambleton and S. McMahon,Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. Agents and Actions29, 338–332 (1990).

    Article  Google Scholar 

  9. T. Ogawa, M. Inazu, K. Gotoh and S. Hayashi,Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. Agents and Actions, in press (1990).

  10. G. H. Thoenes, T. Sitter, K. H. Langer, R. R. Bartlett and R. Schleyerbach,Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int. J. Immunopharmac.11, 921–929 (1989).

    Google Scholar 

  11. R. Peper, B. Alvarez, C. Colombo and H. Schroder,The use of a standardized adjuvant arthritis assay to differentiate between anti-inflammatory and immunosuppressive agents. Proc. Soc. exp. Biol. Med.137, 506–512 (1971).

    Google Scholar 

  12. M. Hang, A. N. Theofilopoulos and F. J. Dixon,A spontaneous rheumatoid arthritis-like disease in MRL/1 mice. J. of Exp. Med.155, 1690–1701 (1982).

    Article  Google Scholar 

  13. A. N. Theofilopoulos and F. J. Dixon,Etiopathogenesis of murine SLE. Immunological Review55, 179–216 (1981).

    Google Scholar 

  14. H. G. Fassbender,Joint destruction in various arthritic diseases. InArticular cartilage biochemistry (Eds. K. E. Kuettner, R. Schleyerbach and V. C. Hascall) pp. 371–389 (1986).

  15. D. E. McFarlin, S. E. Blank, R. F. Kibler, S. McKneally and R. Shapira,Experimental allergic encephalomyelitis in the rat: response to encephalitogenic proteins and peptides. Sciences179, 478–483 (1973).

    Google Scholar 

  16. F. Mokhtarian, D. E. McFarlin and C. S. Raine,Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature309, 356–358 (1984).

    Article  PubMed  Google Scholar 

  17. H. Lassmann, G. Suchanek, K. Kitz, H. Stemberger, B. Schwerer and H. Bernheimer,Antibodies in the pathogenesis of demyelination in chronic relapsing EAE (cr-EAE). InExperimental allergic encephalomyelitis: a useful model for multiple sclerosis (Eds. E. C. Alvord, M. W. Kies and A. J. Suckling) pp. 165–170 Alan R. Liss, Inc., New York (1984).

    Google Scholar 

  18. E. C. Alvord,The challenge: How good a model of MS is EAE today? InExperimental allergic encephalomyelitis: a useful model for multiple sclerosis (Eds. E. C. Alvord, M. W. Kies and A. J. Suckling), pp. 3–5 Alan R. Liss, Inc., New York (1984).

    Google Scholar 

  19. G. H. Thoenes, T. Umscheid, T. Sitter and K. H. Langer,Cyclosporin A inhibits autoimmune experimental tubulointerstitial nephritis. Immunology Letters15, 301–306 (1987).

    Article  PubMed  Google Scholar 

  20. E. Gleichmann, E. H. Elven and J. P. W. Veen,A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE. Eur. J. Immunol.12, 152–159 (1982).

    PubMed  Google Scholar 

  21. C. S. Via, S. O. Sharrow and G. M. Shearer,Role of cytotoxic T lymphocytes in the prevention of Lupus-like disease occuring in a murine model of graft-vs-host disease. J. Immunol.139, 1840–1849 (1987).

    PubMed  Google Scholar 

  22. R. C. Kuppers, T. Suiter, E. Gleichmann and N. R. Rose,The induction of organ-specific antibodies during the graft-vs-host reaction. Eur. J. Immunol.18, 161–166 (1988).

    PubMed  Google Scholar 

  23. R. R. Bartlett,Cyclophosphamide. InThe pahrmacology of lymphocytes (Eds. M. A. Bray and J. Morley), pp. 453–469 Springer-Verlag, Berlin, Heidelberg, New York, (1988).

    Google Scholar 

  24. C. C. A. Küchle, G. H. Thoenes, K. H. Langer, H. U. Schorlemmer, R. R. Bartlett, and R. Schleyerbach,Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transp. Proc. (in press).

  25. D. Bunjes, C. Hardt, M. Röllinghoff and H. Wagner,Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur. J. Immunol.11, 657–661 (1981).

    PubMed  Google Scholar 

  26. R. R. Bartlett,Immunopharmacological profile of HWA 486, a novel isoxazol derivative- II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone or cyclosporin A. Int. J. Immunopharmac.8, 199–204 (1986).

    Article  Google Scholar 

  27. M. Ennis and F. L. Pearce,Differential reactivity of isolated mast cells from the rat and guinea pig. Eur. J. Pharmacol.66, 339–343 (1980).

    Article  PubMed  Google Scholar 

  28. M. Ennis, F. L. Pearce and P. M. Weston,Some studies on the release of histamine from mast cells stimulated with polylsine. Br. J. Pharmacol.70, 329–332 (1980).

    PubMed  Google Scholar 

  29. J. S. Goodwin,Regulation of T cell activation by leukotriene B4. Immunol. Res.5, 233–248 (1986).

    PubMed  Google Scholar 

  30. A. Schimpel, L. Hübner, C. A. Wong and E. Wecker,Distinction between T helper cell replacing factor (TRF) and T cell growth factor (TCGF). Behring Inst. Mitt.67, 221–225 (1980).

    Google Scholar 

  31. R. Palacios, G. Henson, M. Steinmetz and J. P. Kearn,Interleukine-3 supports growth of mouse pre-B-cell clones in vitro. Nature309, 126–131 (1984).

    Article  PubMed  Google Scholar 

  32. M. Kimoto, V. Kindler, M. Higaki, C. Ody, S. Izui and P. Vassalli,Recombinant murine IL-3 fails to stimulate T or B lymphopoiesis in vivo, but enhances immune response to T cell-dependent antigens. J. Immunol.140, 1889–1894 (1988).

    PubMed  Google Scholar 

  33. T. Kalland,Physiology of natural killer cells in vivo regulation of progenitors by interleukin 3. J. Immunol.139, 3671–3675 (1987).

    PubMed  Google Scholar 

  34. W. E. Paul, J. Ohara,B cell stimulatory factor-1/interleukin 4. Ann. Rev. Immunol.5, 429–459 (1987).

    Google Scholar 

  35. H. Wagner, C. Hardt, K. Heeg, K. Pfizenmaier, W. Solbach, R. R. Bartlett, H. Stockinger and M. Röllinghoff,T-T cell interactions during cytotoxic T lymphocyte (CTL) responses: T cell derived helper factor (interleukin 2) as a probe to analyze CTL responsiveness and thymic maturation of CTL progenitors. Immunol. Rev.51, 215–255 (1980).

    PubMed  Google Scholar 

  36. Y. Yarden and A. Ullrich,Growth factor receptor tyrosine kinases. Annu. Rev. Biochem.57, 443–478 (1988).

    Article  PubMed  Google Scholar 

  37. M. D. Waterfield,Epidermal growth factor and related molecules. Lancet, 1243–1246 (1989).

  38. L. J. Pike,Assay of growth factor-stimulated tyrosine kinases using synthetic peptide substrates. Methods Enzamol.146, 353–363 (1987).

    Google Scholar 

  39. G. B. Mills, C. May, M. McGill, M. Fung, M. Baker, R. Sutherland and W. C. Greene,Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor β is tyrosine phosphorylated. J. Biol. Chem.265, 3561–3567 (1990).

    PubMed  Google Scholar 

  40. S. L. Pelech, H. B. Paddon, D. L. Charest and B. S. Federspiel,IL-3-induced activation of protein kinases in the mast cell/megakaryocyte R6-Xe.4 line. J. Immunol.144, 1759–1766 (1990).

    PubMed  Google Scholar 

  41. J. P. M. Evans, A. R. Mire-Sluis, A. V. Hoffbrand and R. G. Wickremasinghe,Binding of G-CSF, GM-CSF, tumor necrosis factor-α and τ-interferon to cell surface receptors on human myeloid leukemia cells triggers rapid tyrosine and serine phosphorylation of a 75-Kd protein. Blood75, 88–95 (1990).

    PubMed  Google Scholar 

  42. B. Gasllis, K. S. Pricket, J. Jackson, J. Slack, K. Schooley, J. E. Sims, S. K. Dower,IL-1 induce rapid phosphorylation of the IL-1 receptor. J. Immunol.143, 3235–3240 (1989).

    PubMed  Google Scholar 

  43. H. L. Goldberg, M. M. Viegas, B. L. Margolis, J. Schlessinger, and L. L. Skorecki,The tyrosine kinase activity of the epidermal-growth-factor receptor is necessary for phospholipase A 2 activation.Biochem. J. 267, 461–465 (1990).

    PubMed  Google Scholar 

  44. B. L. Gruber, L. D. Kaufman, M. J. Marchese, W. Roth, A. P. Kaplan,Anti-IgE autoantibodies in systemic lupus erythematosus. Prevalence and biologic activity. Arthritis & Rheumatism31, 1000–1006 (1988).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacological Research, Hoechst AG Werk Albert, W-6200, Wiesbaden 12, FRG

    R. R. Bartlett & R. Schleyerbach

  2. Immunology Research Center, Belgrade, Yugoslavia

    M. Dimitrijevic

  3. Immunology, Johannes Gutenberg University, W-6500, Mainz, FRG

    T. Mattar, T. Zielinski, T. Germann & E. Rüde

  4. Medical Clinic, Ludwig-Maximilians University, W-8000, Munich 2, FRG

    G. H. Thoenes & C. C. A. Küchle

  5. Behring Research Laboratories, W-3550, Marburg, FRG

    H. -U. Schorlemmer

  6. Department of Medicine, Rush Medical Center, Chicago, Ill, USA

    E. Bremer & A. Finnegan

Authors
  1. R. R. Bartlett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Dimitrijevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Mattar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Zielinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Germann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Rüde
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. H. Thoenes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. C. A. Küchle
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. -U. Schorlemmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E. Bremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. Finnegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R. Schleyerbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartlett, R.R., Dimitrijevic, M., Mattar, T. et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents and Actions 32, 10–21 (1991). https://doi.org/10.1007/BF01983301

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01983301

Keywords

Search

Navigation